title: Stevens-Johnson syndrome associated with reduced tear production complicating the use of cetuximab and panitunumab.
authors.forename: Francesco
authors.initials: F
authors.lastname: Pantano
authors.forename: Marianna
authors.initials: M
authors.lastname: Silletta
authors.forename: Alfonso
authors.initials: A
authors.lastname: Iovieno
authors.forename: Bruno
authors.initials: B
authors.lastname: Vincenzi
authors.forename: Daniele
authors.initials: D
authors.lastname: Santini
authors.forename: Sara
authors.initials: S
authors.lastname: Galluzzo
authors.forename: Stefano
authors.initials: S
authors.lastname: Bonini
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Tonini
mesh_terms: D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000068818:Cetuximab; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000556:secondary; D008875:Middle Aged; D013262:Stevens-Johnson Syndrome / Q000209:etiology*; D013666:Tears / Q000378:metabolism*
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C545242:panitunumab; D000068818:Cetuximab